How Pharmather is Using Human Organoid Models for Research in the Psychedelic Space

In Part #2 of our interview with Pharmather (CSE: PHRM) CEO Fabio Chianelli we discuss how the company has carved out their own niche through FDA approved type psychedelics that focus on Ketamine, and where they position themselves amongst other companies within the psychedelic space.

In addition, through their research Pharmather is constructing their own internal data along with their partnership with the UHN. The data is developed through human organoid models using specific in vitro type methods.

Pharmather Inc., is a wholly subsidiary of Newscope Capital Corporation and a specialty life sciences company that focuses on the research and development of psychedelic pharmaceuticals.

The Dales Report Inc. disclosure policy applies to this post    
You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More